Navigation Links
New Addition to the Prostate Cancer Roundtable Policy Agenda Addresses Quality-of-Life Endpoints
Date:12/18/2013

WASHINGTON, Dec. 18, 2013 /PRNewswire/ -- The Prostate Cancer Roundtable has updated its shared national policy agenda for 2014 to include a new policy priority, based on the idea that Phase III clinical trials of new drugs and other forms of treatment that are being tested for their ability to extend overall or progression-free survival should, at the same time, be evaluated for their impact on at least one patient-reported outcome that affects quality of life—at least as a secondary endpoint. For example, does treatment with this drug delay onset of bone pain in men with disseminated prostate cancer?

On Monday, December 9, those attending the Prostate Cancer Roundtable meeting voted unanimously to approve the suggested language and add a new section to the Policy Agenda to read:

"We seek and encourage the inclusion of quality-of-life-related endpoints, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival—such that quality-of-life-related data (positive or negative) as well as survival data can be included in labeling for products indicated for treatment of prostate cancer as and when appropriate."

This revised policy agenda can be found at www.prostatecancerroundtable.net/agenda and serves as the group's policy priorities in discussions with legislators, media and advocates over the next year. The twelve organizations of the Prostate Cancer Roundtable represent the national organizations leading the fight against prostate cancer and speaking on behalf of the hundreds of thousands of patients diagnosed with prostate cancer each year and the estimated 2.2 million men and their families living today who have been diagnosed with the disease.

"While we appreciate the heroic and essential efforts of drug developers, the FDA, and the clinical research community to improve overall patient survival, we also believe that it is critical to patients and families that we study whether life-extending new treatments also have impact on quality of life," said Thomas Kirk, CEO, Us TOO International.

"We're hoping that our inclusion of quality-of-life endpoints as part of our policy agenda will resonate with those stakeholders directly involved with providing prostate cancer care," said Tom Farrington, Founder and President, Prostate Health Education Network. "This is an ambitious but worthy goal which will result in better care for those who not only want their lives extended but also desire a life as close to possible as before the disease."

"Life extension is valuable for patients and the prostate cancer community as a whole," said Wendy Poage, President, Prostate Conditions Education Council. "But being able to also enjoy life, without extensive side effects from treatments and without painful symptoms from their cancer is in many cases, just as important for cancer patients. By including quality of life measures in clinical trials, we will not only better understand the impact of new treatments on patients, but this new policy agenda may also help draw attention to patient-centered concerns and provide better cancer care."

About the Prostate Cancer Roundtable:
The Prostate Cancer Roundtable, representing America's prostate cancer community, is a group of independent, patient-centric, not-for-profit organizations that cooperate to foster the development of policies supporting high quality prostate cancer research, the prevention and early detection of clinically significant prostate cancer, the appropriate care and effective treatment of men with prostate cancer, and the appropriate education of all men at risk for this disease.

The members of the Prostate Cancer Roundtable are:
- Ed Randall's Fans for the Cure (www.fans4thecure.org)
- Malecare Prostate Cancer Support (www.malecare.org)
- Men's Health Network (www.menshealthnetwork.org)
- National Alliance of State Prostate Cancer Coalitions (www.naspcc.org)
- Prostate Cancer International (www.pcainternational.org)
- Prostate Conditions Education Council (www.prostateconditions.org)
- Prostate Health Education Network (www.prostatehealthed.org)
- The Prostate Net (www.prostatenet.org)
- Us TOO International Prostate Cancer Education and Support Network (www.ustoo.org)
- Women Against Prostate Cancer (www.womenagainstprostatecancer.org)
- ZERO - The End of Prostate Cancer (www.zerocancer.org)

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.


'/>"/>
SOURCE Prostate Cancer Roundtable
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ACell Nearly Doubles Board of Directors with Addition of Three Members
2. Cyberonics Announces Expansion of Share Repurchase Program By An Additional One Million Shares
3. Roche receives FDA clearance to use additional specimen types for chlamydia and gonorrhea test
4. RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
5. Bruin Biometrics Formalizes Management Structure with Appointment of Jeff Greiner and Eve Kurtin to Board of Directors, Plus Additional Executive Leadership
6. Actinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actiniums Actimab-A to Be Presented at American Society of Hematology Annual Meeting
7. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
8. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 6 Million Shares of Stock through Calendar Year 2014
9. Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Initial Public Offering of Common Stock
10. Middle Peak Medical Raises an Additional $3M to Develop Novel Mitral Valve Technology
11. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):